Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223896227> ?p ?o ?g. }
- W4223896227 endingPage "3045" @default.
- W4223896227 startingPage "3031" @default.
- W4223896227 abstract "Abstract Aerobic glycolysis is a well‐known hallmark of hepatocellular carcinoma (HCC). Hence, targeting the key enzymes of this pathway is considered a novel approach to HCC treatment. The effects of sodium butyrate (NaBu), a sodium salt of the short‐chain fatty acid butyrate, on aerobic glycolysis in HCC cells and the underlying mechanism are unknown. In the present study, data obtained from cell lines with mouse xenograft model revealed that NaBu inhibited aerobic glycolysis in the HCC cells in vivo and in vitro . NaBu induced apoptosis while inhibiting the proliferation of the HCC cells in vivo and in vitro . Furthermore, the compound inhibited the release of lactate and glucose consumption in the HCC cells in vitro and inhibited the production of lactate in vivo . The modulatory effects of NaBu on glycolysis, proliferation and apoptosis were related to its modulation of hexokinase 2 (HK2). NaBu downregulated HK2 expression via c‐myc signalling. The upregulation of glycolysis in the HCC cells induced by sorafenib was impeded by NaBu, thereby enhancing the anti‐HCC effect of sorafenib in vitro and in vivo . Thus, NaBu inhibits the expression of HK2 to downregulate aerobic glycolysis and the proliferation of HCC cells and induces their apoptosis via the c‐myc pathway." @default.
- W4223896227 created "2022-04-19" @default.
- W4223896227 creator A5000441787 @default.
- W4223896227 creator A5002047602 @default.
- W4223896227 creator A5008110283 @default.
- W4223896227 creator A5010350116 @default.
- W4223896227 creator A5013617878 @default.
- W4223896227 creator A5027134161 @default.
- W4223896227 creator A5032617409 @default.
- W4223896227 creator A5037006855 @default.
- W4223896227 creator A5037249009 @default.
- W4223896227 creator A5038386460 @default.
- W4223896227 creator A5059119214 @default.
- W4223896227 creator A5073501391 @default.
- W4223896227 creator A5090473887 @default.
- W4223896227 date "2022-04-16" @default.
- W4223896227 modified "2023-10-16" @default.
- W4223896227 title "Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c‐myc/hexokinase 2 pathway" @default.
- W4223896227 cites W1486720764 @default.
- W4223896227 cites W1700829084 @default.
- W4223896227 cites W1893330971 @default.
- W4223896227 cites W2011100088 @default.
- W4223896227 cites W2012388327 @default.
- W4223896227 cites W2025115267 @default.
- W4223896227 cites W2033483604 @default.
- W4223896227 cites W2045102424 @default.
- W4223896227 cites W2079162697 @default.
- W4223896227 cites W2081826708 @default.
- W4223896227 cites W2093410497 @default.
- W4223896227 cites W2093985232 @default.
- W4223896227 cites W2117692326 @default.
- W4223896227 cites W2146885685 @default.
- W4223896227 cites W2166701473 @default.
- W4223896227 cites W2223535266 @default.
- W4223896227 cites W2334702496 @default.
- W4223896227 cites W2344235126 @default.
- W4223896227 cites W2344663917 @default.
- W4223896227 cites W2486207088 @default.
- W4223896227 cites W2516191599 @default.
- W4223896227 cites W2561131502 @default.
- W4223896227 cites W2566991267 @default.
- W4223896227 cites W2571212804 @default.
- W4223896227 cites W2590130858 @default.
- W4223896227 cites W2601891236 @default.
- W4223896227 cites W2604237554 @default.
- W4223896227 cites W2607628579 @default.
- W4223896227 cites W2622362587 @default.
- W4223896227 cites W2625811471 @default.
- W4223896227 cites W2748826812 @default.
- W4223896227 cites W2750632207 @default.
- W4223896227 cites W2754521784 @default.
- W4223896227 cites W2801000404 @default.
- W4223896227 cites W2801588198 @default.
- W4223896227 cites W2885329437 @default.
- W4223896227 cites W2889488326 @default.
- W4223896227 cites W2901515479 @default.
- W4223896227 cites W2903026114 @default.
- W4223896227 cites W2918298756 @default.
- W4223896227 cites W2922234004 @default.
- W4223896227 cites W2937074604 @default.
- W4223896227 cites W2947720408 @default.
- W4223896227 cites W2953686308 @default.
- W4223896227 cites W2962872270 @default.
- W4223896227 cites W2965102054 @default.
- W4223896227 cites W2967744502 @default.
- W4223896227 cites W2969535179 @default.
- W4223896227 cites W2971119545 @default.
- W4223896227 cites W2986542746 @default.
- W4223896227 cites W3006323131 @default.
- W4223896227 cites W3012029599 @default.
- W4223896227 cites W3013551968 @default.
- W4223896227 cites W3014584997 @default.
- W4223896227 cites W3036081919 @default.
- W4223896227 cites W3038789517 @default.
- W4223896227 cites W3049568686 @default.
- W4223896227 cites W3096588955 @default.
- W4223896227 cites W3101823935 @default.
- W4223896227 cites W3109500484 @default.
- W4223896227 cites W3110872158 @default.
- W4223896227 cites W3119562168 @default.
- W4223896227 cites W3120352650 @default.
- W4223896227 cites W3123924757 @default.
- W4223896227 cites W3167224911 @default.
- W4223896227 cites W3204325474 @default.
- W4223896227 cites W4223896227 @default.
- W4223896227 doi "https://doi.org/10.1111/jcmm.17322" @default.
- W4223896227 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35429101" @default.
- W4223896227 hasPublicationYear "2022" @default.
- W4223896227 type Work @default.
- W4223896227 citedByCount "14" @default.
- W4223896227 countsByYear W42238962272022 @default.
- W4223896227 countsByYear W42238962272023 @default.
- W4223896227 crossrefType "journal-article" @default.
- W4223896227 hasAuthorship W4223896227A5000441787 @default.
- W4223896227 hasAuthorship W4223896227A5002047602 @default.
- W4223896227 hasAuthorship W4223896227A5008110283 @default.
- W4223896227 hasAuthorship W4223896227A5010350116 @default.
- W4223896227 hasAuthorship W4223896227A5013617878 @default.